A diabetes drug could lead to new treatment for recurrent miscarriage

A pilot trial led by Tommy’s National Centre for Miscarriage Research suggests diabetes drug could be repurposed to target the lining of the womb in women with recurrent miscarriage.

January 9 2020

A drug designed to tackle diabetes could also be repurposed as the first treatment to prevent miscarriage by targeting the lining of the womb, according to a clinical trial led by Tommy’s National Centre for Miscarriage Research at the University of Warwick.

Recurrent miscarriage is defined as the loss of 3 or more consecutive pregnancies, with each additional miscarriage decreasing the likelihood of a successful pregnancy. Previous research by the Warwick team found that women who experience recurrent miscarriages do not have enough of a special type of cell in the lining of their wombs: stem cells. These are unspecialised cells that can turn into many other types of cell.

Stem cells and recurrent miscarriage 

Many cells in the womb are renewed often, for example after a woman’s period when the lining of the womb regrows. Stem cells are essential in this process. Without them, our body’s tissues age faster – this in turn can cause inflammation that could be harmful to the growing baby, leading to miscarriage.

Researchers identified an enzyme – called DPP4 for short – which they believe is too active in women with a history of recurrent miscarriage. This enzyme can stop stem cells getting from the blood into the lining of the womb. 

A new class of diabetes drugs targets this enzyme. The researchers investigated whether reducing this enzyme using this drug, sitagliptin, would increase the number of stem cells in the lining of the womb and improve conditions in the womb for pregnancy.

In a pilot clinical trial, 38 women aged 18 to 42 who had experienced a high number of recurrent miscarriages were given either a course of sitagliptin or a placebo for 3 menstrual cycles. Biopsies of the womb were taken at the start of the course of treatment and afterwards to determine the number of stem cells present before and after the course.

Researchers found an average increase in stem cell count of 68% in those women who took the full course of sitagliptin. This compares to no significant increase in those in the control group receiving an identical placebo pill. They also saw a 50% decrease in the number of ‘stressed’ cells present in the lining of the womb. There were also minimal side effects for the participants.

“We have improved the environment that an embryo develops in and in doing so we hope to improve the chances of a successful pregnancy. Although this research was specifically designed to test whether we could increase the presence of stem cells in the womb, follow-up of participants found that there were no further losses of normal pregnancies in those who took sitagliptin. These are very early results and the treatment now needs to be further tested in a large-scale clinical trial.”

Professor Siobhan Quenby from Warwick Clinical Trials Unit and an Honorary Consultant at University Hospital Coventry and Warwickshire NHS Trust

Stem cells play a key role in creating decidual cells in the womb lining which support the placenta throughout pregnancy. Insufficient stem cells in the womb lining leads to an excess of stressed and inflammatory decidual cells, which in turn may cause placental bleeding and miscarriage. Sitagliptin was effective not only in increasing stem cells in the womb lining but also decreasing the quantity of stressed decidual cells. 

“There are currently very few effective treatments for miscarriage, and this is the first that aims at normalising the womb before pregnancy. Although miscarriages can be caused by genetic errors in the embryo, an abnormal womb lining causes the loss of chromosomally normal pregnancies. We hope that this new treatment will prevent such losses and reduce both the physical and psychological burden of recurrent miscarriage.”

Professor Jan Brosens, of Warwick Medical School and Consultant in Reproductive Health at University Hospitals Coventry and Warwickshire NHS Trust

A potential treatment to prevent miscarriage 

The researchers now hope to take the treatment to clinical trial and, if successful, it would be the first targeted specifically at the lining of the womb to prevent miscarriage.

 “For far too long it has often been said by many health professionals that miscarriage is not preventable, and parents have been left with little hope given the lack of treatment options available. This situation prompted Tommy’s to invest in the Tommy’s National Centre for Miscarriage Research and this breakthrough research by the world leading team at Warwick shows great promise for an effective treatment which will reduce miscarriage and possibly later pregnancy loss too.”

Jane Brewin, Chief Executive at Tommy’s

The research has been published today in the journal EBioMedicine from research conducted with University Hospitals Coventry and Warwickshire and supported by the NIHR Coventry and Warwickshire Clinical Research Facility.

If you’ve experienced miscarriage, you can find support and information here.

Read more about Tommy’s research into miscarriage.

 

Make a donation to Tommy's

Learn more about Tommy's pioneering reasearch

  • Predicting and preventing premature birth

    Premature birth is the biggest killer of newborn babies in the UK and much of Tommy's research is devoted to predicting and preventing this. One discovery has made a huge difference to our ability to treat women in time.

  • Finding the reasons for stillbirth

    In more than half of stillbirths parents are not given a reason for their babies' death. Doctors simply do not know why it happens. This animation looks at how Tommy's researchers are finding out the causes of stillbirth and how this leads to treatments and saved lives.

  • Finding the reasons for miscarriage

    Too many miscarriages are unexplained. Our research is entirely dedicated to finding out why miscarriages happen and how to prevent it in the future.

Read more Tommy's News

  • A nurse taking a patients blood pressure in a hospital room

    News

    Pregnancy is a unique chance to predict health risks to mums

    A recently published article, co-authored by Professor Catherine Williamson from Tommy’s Research Centre at King’s College London, suggests that certain pregnancy complications can indicate future health issues for women.

  • Rising demand for Tommy's midwives in coronavirus lockdown

    News

    Tommy’s awarded grant to help meet rising demand for support during coronavirus lockdown

    Tommy’s has received a grant from the UK Government’s Department for Health and Social Care to support the costs of its PregnancyHub information and support services throughout the summer, due to rising demand in the wake of coronavirus.

  • Tommy's researchers latest findings

    News

    Tommy’s Research Centres continue vital work on pregnancy complications

    Although recruitment to some clinical trials had to be paused when coronavirus hit the UK, scientists at Tommy’s Research Centres across the UK are still hard at work, supporting women and families in our specialist clinics and sharing their latest studies with academic journals.

  • Blog

    Miscarriage during lockdown

    The day before Mother’s Day, and two days before the UK officially went into coronavirus lockdown, Zara Dawson found out she was having a miscarriage. Her third consecutive miscarriage in less than a year, and fourth consecutive loss, after losing her second son Jesse in 2018 to termination for medical reasons.

    Was this information useful?

    Yes No